Previous 10 | Next 10 |
Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it...
UroGen Pharma Ltd. (URGN) Q4 2020 Results Earnings Conference Call March 18, 2021, 8:30 AM ET Company Participants Sara Sherman - Head, Investor Relations Liz Barrett - President and CEO Dr. Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - Chief F...
UroGen Pharma (URGN) trades 4.6% higher premarket after entering into a strategic funding agreement with RTW Investments wherein the company will receive $75M in upfront cash from RTW in return for tiered, future cash payments based on aggregate worldwide annual net product sales of...
UroGen Pharma (URGN): Q4 GAAP EPS of -$1.38 misses by $0.01.Revenue of $7.97M beats by $0.4M.Press Release For further details see: UroGen Pharma EPS misses by $0.01, beats on revenue
Achieved Jelmyto ® net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seven months of commercialization Initiated ATLAS Phase III trial for UGN-102 and actively enrolling patients with low-grade intermediate risk NMIBC ...
RTW Investments, LP will provide UroGen with an upfront cash payment of $75 million and will receive tiered future payments based on worldwide annual net product sales of Jelmyto ® and UGN-102, if approved Strategic funding partnership with RTW Investments, LP e...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event. For further details see: Urogen Pharma (URGN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
Exploratory research at the Johns Hopkins University to study checkpoint inhibitors combined with RTGel ™ in Glioblastoma Multiforme UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat...
Conference Call and Webcast Scheduled for Thursday, March 18, 2021 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that ...
UroGen is using its proprietary reverse thermal gel technology to pioneer a line of therapies for upper urinary tract cancers that are substantially better than current options. Jelmyto is already on the market with estimated peak sales around $375 million, but UGN-102 is about to sta...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...